To spearhead this expansion, the company has appointed Eric Creveling as Principal Engineer for Pharma and Device Testing. Creveling arrives with two decades of experience and a history of managing FDA-registered, cGMP-compliant laboratories. His technical oversight is intended to align PCL’s new infrastructure with stringent pharmaceutical standards immediately upon launch.
CEO and co-founder Matthew Lapham stated that the investment in state-of-the-art capital equipment is a response to specific requests from CDMOs and pharmaceutical firms. By integrating this specialized testing suite, PCL aims to replicate the service model it established within the medical device industry, focusing on rapid turnaround times and rigorous quality control for clients navigating complex product development cycles.




Comments (0)
No comments yet. Be the first!